Evidence map›Paper›PMID 40788823›Full record

Trial reportAmerican journal of respiratory and critical care medicine2025

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial.

Isabelle Durieu, Barry Clements, Benedetta Fabrizzi, Marcus A Mall, Edward McKone, Bonnie Ramsey, Elizabeth Tullis, Jennifer L Taylor-Cousar, Renske van der Meer, Eric Bachman and 6 more

Abstract readClinical Trial, Phase III
PubMed Publisher
In one paragraph

Trial report in American journal of respiratory and critical care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Isabelle DurieuHospices Civils de Lyon, Groupe Hospitalier Sud, Research on Healthcare Performance, INSERM U1290, Universite Claude Bernard Lyon, Lyon, France.
Barry ClementsPerth Children's Hospital, Perth, Western Australia, Australia.
Benedetta FabrizziAzienda Ospedaliero Universitaria delle Marche, Ancona, Italy.ORCID 0000-0003-2358-5470
Marcus A MallDepartment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID 0000-0002-4057-2199
Edward McKoneSt. Vincent's University Hospital, Dublin, Ireland.ORCID 0000-0002-5455-8208
Bonnie RamseySeattle Children's Hospital, Seattle, Washington.
Elizabeth TullisSt. Michael's Hospital, Toronto, Ontario, Canada.
Jennifer L Taylor-CousarNational Jewish Health, Denver, Colorado.ORCID 0000-0002-5436-9722
Renske van der MeerHaga Hospital, the Hague, the Netherlands.
Eric BachmanVertex Pharmaceuticals, Inc., Boston, Massachusetts.
Anna ChinVertex Pharmaceuticals, Inc., Boston, Massachusetts.
Sarah ConnerVertex Pharmaceuticals, Inc., Boston, Massachusetts.
Mark JenningsVertex Pharmaceuticals, Inc., Boston, Massachusetts.
Tanya WeinstockVertex Pharmaceuticals, Inc., Boston, Massachusetts.
Carla ColomboFondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Philip RobinsonRoyal Children's Hospital, Melbourne, Victoria, Australia.

Funding

Vertex Pharmaceuticals
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AminophenolsBenzodioxolesCystic FibrosisGlucose IntoleranceIndolesPhenylpropionatesPyrrolidinesQuinolonesAdolescentAdultBlood GlucoseCystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationsFemaleGlucose Tolerance TestHumansAminophenolsBenzodioxolesBlood GlucoseCystic Fibrosis Transmembrane Conductance RegulatorDrug Combinationselexacaftorelexacaftor, ivacaftor, tezacaftor drug combinationIndolesivacaftorPhenylpropionatesPyrazolesPyridinesPyrrolidinesQuinolinesQuinolonestezacaftorcystic fibrosiselexacaftorglucose toleranceivacaftortezacaftor

Identifiers

PMID40788823

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.